000			01998 a2200553 4500
005			20250516193405.0
264		0	_c20140930
008			201409s 0 0 eng d
022			_a1559-131X
024	7		_a10.1007/s12032-014-0845-3 _2doi
040			_aNLM _beng _cNLM
100	1		_aWei, Zheng
245	0	0	_aHBsAg is an independent prognostic factor in diffuse large B cell lymphoma patients in rituximab era: result from a multicenter retrospective analysis in China. _h[electronic resource]
260			_bMedical oncology (Northwood, London, England) _cMar 2014
300			_a845 p. _bdigital
500			_aPublication Type: Journal Article; Multicenter Study
650	0	4	_aAntibodies, Monoclonal, Murine-Derived _xadministration & dosage
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aChina
650	0	4	_aCyclophosphamide _xadministration & dosage
650	0	4	_aDoxorubicin _xadministration & dosage
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aHepatitis B _xcomplications
650	0	4	_aHepatitis B Surface Antigens _xmetabolism
650	0	4	_aHepatitis B virus _xgenetics
650	0	4	_aHumans
650	0	4	_aLymphoma, Large B-Cell, Diffuse _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm Staging
650	0	4	_aPrednisone _xadministration & dosage
650	0	4	_aPrognosis
650	0	4	_aRetrospective Studies
650	0	4	_aRituximab
650	0	4	_aSurvival Rate
650	0	4	_aVincristine _xadministration & dosage
700	1		_aZou, Shanhua
700	1		_aLi, Feng
700	1		_aCheng, Zhixiang
700	1		_aLi, Junmin
700	1		_aWang, Jianmin
700	1		_aWang, Chun
700	1		_aChen, Fangyuan
700	1		_aCao, Junning
700	1		_aCheng, Yunfeng
773	0		_tMedical oncology (Northwood, London, England) _gvol. 31 _gno. 3 _gp. 845
856	4	0	_uhttps://doi.org/10.1007/s12032-014-0845-3 _zAvailable from publisher's website
999			_c23491226 _d23491226